<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C09C&quot;,&quot;href&quot;:&quot;atc/C09C.md&quot;},{&quot;label&quot;:&quot;losartan&quot;}]"></div>

# losartan

- **generic name:** losartan
- **ATC codes:** `C09CA01`, `C09DA01`, `C09DB06`
- **DrugBank:** [DB00678](https://go.drugbank.com/drugs/DB00678) · **PubChem:** [CID 3961](https://pubchem.ncbi.nlm.nih.gov/compound/3961)
- **molar mass:** 422.911 g/mol (C22H23ClN6O) — DrugBank
- **groups:** approved, investigational

## About

It is widely used worldwide and is included on the WHO list of essential medicines, also available in fixed combinations with diuretics or calcium channel blockers.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q410074](https://www.wikidata.org/wiki/Q410074) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-30 18:20 | 1:06:44 | 0/0/0 | 0/0/0 | 5/0/1 | 291,690/94,364 | openai / gpt-6-luna | 17 | 12/9 | 16/1 | 0 |

## popPK records

_not available_

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--neutral" title="a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.">safety allele</span> | **CYP2C9** | `safety` — adverse-reaction risk (HLA / safety allele) — no parameter shift | safety_allele | [Goktaş_2015](drugs/drug_losartan/pgx_Gokta_2015_CYP2C9_safety.md) | Goktaş MT et al., Lower CYP2C9 activity in Turkish patien…, European journal of clinica… (2015) | [10.1007/s00228-015-1899-7](https://doi.org/10.1007/s00228-015-1899-7) |
| <span class="pk-badge pk-badge--neutral" title="a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.">safety allele</span> | **CYP2C9** | `safety` — adverse-reaction risk (HLA / safety allele) — no parameter shift | safety_allele | [Luo_2014](drugs/drug_losartan/pgx_Luo_2014_CYP2C9_safety.md) | Luo SB et al., Characterization of a novel CYP2C9 muta…, Journal of pharmacological… (2014) | [10.1254/jphs.13189fp](https://doi.org/10.1254/jphs.13189fp) |
| <span class="pk-badge pk-badge--neutral" title="a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.">safety allele</span> | **CYP2C9** | `safety` — adverse-reaction risk (HLA / safety allele) — no parameter shift | safety_allele | [Pedreros-Rosales_2019](drugs/drug_losartan/pgx_Pedreros_Rosales_2019_CYP2C9_safety.md) | Pedreros-Rosales C et al., [Association between cytochrome p4502c9…, Revista medica de Chile (2019) | [10.4067/S0034-98872019001201527](https://doi.org/10.4067/S0034-98872019001201527) |
| <span class="pk-badge pk-badge--neutral" title="a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.">safety allele</span> | **CYP2C9** | `safety` — adverse-reaction risk (HLA / safety allele) — no parameter shift | safety_allele | [Yin_2008](drugs/drug_losartan/pgx_Yin_2008_CYP2C9_safety.md) | Yin T et al., Genetic variations of CYP2C9 in 724 Jap…, Hypertension research : off… (2008) | [10.1291/hypres.31.1549](https://doi.org/10.1291/hypres.31.1549) |
| <span class="pk-badge pk-badge--neutral" title="a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.">safety allele</span> | **CYP2C9** | `safety` — adverse-reaction risk (HLA / safety allele) — no parameter shift | safety_allele | [Zhou_2021](drugs/drug_losartan/pgx_Zhou_2021_CYP2C9_safety.md) | Zhou XY et al., Identification and Enzymatic Activity E…, Frontiers in pharmacology (2021) | [10.3389/fphar.2021.619339](https://doi.org/10.3389/fphar.2021.619339) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> | **POR** | `Q21` · AUC ratio | metabolism | [Goktaş_2015](drugs/drug_losartan/pgx_Gokta_2015_POR_Q21.md) | Goktaş MT et al., Lower CYP2C9 activity in Turkish patien…, European journal of clinica… (2015) | [10.1007/s00228-015-1899-7](https://doi.org/10.1007/s00228-015-1899-7) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=losartan) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | blood-brain barrier | `ABCB1` inhibitor/substrate | DrugBank actor |
| absorption | kidney | `ABCB1` inhibitor/substrate | DrugBank actor |
| absorption | liver | `ABCB1` inhibitor/substrate | DrugBank actor |
| absorption | placenta | `ABCB1` inhibitor/substrate | DrugBank actor |
| absorption | small intestine | `ABCB1` inhibitor/substrate | DrugBank actor |
| absorption | testis | `ABCB1` inhibitor/substrate | DrugBank actor |
| distribution | blood | `ALB` substrate | DrugBank actor |
| metabolism | kidney | `UGT2B7` substrate | DrugBank actor |
| metabolism | liver | `CYP2C19` inhibitor, `CYP2C8` inhibitor, `CYP2C9` safety_allele/substrate, `CYP3A4` inhibitor/substrate, `POR` metabolism, `UGT1A1` substrate, `UGT1A3` substrate, `UGT2B17` substrate, `UGT2B7` substrate | DrugBank actor |
| metabolism | small intestine | `CYP3A4` inhibitor/substrate, `UGT1A1` substrate, `UGT2B17` substrate, `UGT2B7` substrate | DrugBank actor |
| excretion | bile duct | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | kidney | `SLC22A6` inhibitor | DrugBank actor |
| excretion | liver | `ABCB11` substrate | DrugBank actor |

<sub>Actors without a tissue in the table: AGTR1 (target), EPOR (stimulator), SLC22A12 (inhibitor), SLC2A9 (inhibitor), UGT1A10 (substrate).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 915 matched, 216 returned
- **screened:** 14  ·  **relevant:** 2
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_67 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Christ_1994.pdf` | Christ DD et al., The pharmacokinetics and pharmacodynami…, The Journal of pharmacology… (1994) | popPK | 10 | not captured | [8138932](https://pubmed.ncbi.nlm.nih.gov/8138932) | The dog study reports numeric losartan clearance, volume, half-life, and bioavailability values in the provided evidence. |
| `Karatza_2020.pdf` | Karatza E et al., Modelling gastric emptying: A pharmacok…, Basic & clinical pharmacolo… (2020) | popPK | 10 | [10.1111/bcpt.13321](https://doi.org/10.1111/bcpt.13321) | [31514255](https://pubmed.ncbi.nlm.nih.gov/31514255) | The paper reports a population-PK model for losartan, but no numeric parameter values appear in the provided evidence. |
| `Karatza_2021.pdf` | Karatza E et al., Investigating the Impact of Gastric Emp…, European journal of drug me… (2021) | popPK | 10 | [10.1007/s13318-021-00683-3](https://doi.org/10.1007/s13318-021-00683-3) | [33768449](https://pubmed.ncbi.nlm.nih.gov/33768449) | Losartan is the subject of population-PK models, but no numeric parameter values are provided in the evidence. |
| `Lankford_1997.pdf` | Lankford SM et al., Pharmacokinetic-pharmacodynamic relatio…, Journal of cardiovascular p… (1997) | popPK | 10 | [10.1097/00005344-199711000-00008](https://doi.org/10.1097/00005344-199711000-00008) | [9388040](https://pubmed.ncbi.nlm.nih.gov/9388040) | The porcine study reports numeric losartan clearance, steady-state volume, and half-life in the provided evidence. |
| `Baek_2013.pdf` | Baek IH et al., Pharmacokinetics of angiotensin II rece…, Drug research (2013) | popPK | 9 | [10.1055/s-0033-1341424](https://doi.org/10.1055/s-0033-1341424) | [23539423](https://pubmed.ncbi.nlm.nih.gov/23539423) | Losartan is a dog PK subject with a two-compartment model, but no numeric parameter values are shown in the provided evidence. |
| `Shimizu_2012.pdf` | Shimizu R et al., The pharmacokinetic-pharmacodynamic ass…, Drug metabolism and pharmac… (2012) | popPK | 9 | [10.2133/dmpk.dmpk-11-rg-060](https://doi.org/10.2133/dmpk.dmpk-11-rg-060) | [22076447](https://pubmed.ncbi.nlm.nih.gov/22076447) | The study reports population PK analysis of losartan in rats, but no numeric parameter values are provided in the evidence. |
| `Khandave_2012.pdf` | Khandave SS et al., Bioequivalence study of two losartan ta…, International journal of cl… (2012) | popPK | 7 | [10.5414/cp201521](https://doi.org/10.5414/cp201521) | [22541840](https://pubmed.ncbi.nlm.nih.gov/22541840) | This is an original human losartan PK study, but the provided evidence contains no numeric parameter values. |
| `Reid_1993.pdf` | Reid JL, Inhibitors of the renin-angiotensin sys…, Arzneimittel-Forschung (1993) | pd | 5 | not captured | [8498975](https://www.ncbi.nlm.nih.gov/pubmed/8498975) | metadata signals extractable PD data (concentration-effect) |
| `Reque_2021.pdf` | Reque R et al., Ecotoxicity of losartan potassium in aq…, Environmental toxicology an… (2021) | pd | 5 | [10.1016/j.etap.2021.103727](https://doi.org/10.1016/j.etap.2021.103727) | [34454063](https://www.ncbi.nlm.nih.gov/pubmed/34454063) | metadata signals extractable PD data (EC50) |
| `Baan_1998.pdf` | Baan J et al., Effects of angiotensin II and losartan…, Journal of hypertension (1998) | pd | 4 | [10.1097/00004872-199816090-00011](https://doi.org/10.1097/00004872-199816090-00011) | [9746117](https://www.ncbi.nlm.nih.gov/pubmed/9746117) | metadata signals extractable PD data (Emax) |
| `Bhunia_2017.pdf` | Bhunia SS et al., Molecular modelling studies in explaini…, SAR and QSAR in environment… (2017) | pd | 4 | [10.1080/1062936X.2017.1396247](https://doi.org/10.1080/1062936X.2017.1396247) | [29135287](https://www.ncbi.nlm.nih.gov/pubmed/29135287) | metadata signals extractable PD data (IC50) |
| `Castro-Chaves_2006.pdf` | Castro-Chaves P et al., Endothelin ETA receptors and endotheliu…, European journal of pharmac… (2006) | pd | 4 | [10.1016/j.ejphar.2006.06.020](https://doi.org/10.1016/j.ejphar.2006.06.020) | [16842775](https://www.ncbi.nlm.nih.gov/pubmed/16842775) | metadata signals extractable PD data (Emax) |
| `Chan_2014.pdf` | Chan KH et al., Angiotensin-[1-12] interacts with angio…, Neuropharmacology (2014) | pd | 4 | [10.1016/j.neuropharm.2013.06.022](https://doi.org/10.1016/j.neuropharm.2013.06.022) | [23823979](https://www.ncbi.nlm.nih.gov/pubmed/23823979) | metadata signals extractable PD data (EC50) |
| `Dias_2022.pdf` | Dias CJ et al., Carvacrol reduces blood pressure, arter…, European journal of pharmac… (2022) | pd | 4 | [10.1016/j.ejphar.2021.174717](https://doi.org/10.1016/j.ejphar.2021.174717) | [34953800](https://www.ncbi.nlm.nih.gov/pubmed/34953800) | metadata signals extractable PD data (Emax) |
| `Dickinson_1994.pdf` | Dickinson KE et al., BMS-180560, an insurmountable inhibitor…, British journal of pharmaco… (1994) | pd | 4 | [10.1111/j.1476-5381.1994.tb16191.x](https://doi.org/10.1111/j.1476-5381.1994.tb16191.x) | [7812609](https://www.ncbi.nlm.nih.gov/pubmed/7812609) | metadata signals extractable PD data (EC50) |
| `Fernandes_2025.pdf` | Fernandes EP et al., Removal of emerging pollutants by an ad…, Environmental research (2025) | pd | 4 | [10.1016/j.envres.2025.122259](https://doi.org/10.1016/j.envres.2025.122259) | [40609721](https://www.ncbi.nlm.nih.gov/pubmed/40609721) | metadata signals extractable PD data (EC50) |
| `Fior_1994.pdf` | Fior DR et al., Evidence for an antagonistic angiotensi…, European journal of pharmac… (1994) | pd | 4 | [10.1016/0014-2999(94)90741-2](https://doi.org/10.1016/0014-2999(94)90741-2) | [7813592](https://www.ncbi.nlm.nih.gov/pubmed/7813592) | metadata signals extractable PD data (IC50) |
| `Gloy_1998.pdf` | Gloy J et al., Angiotensin II modulates cellular funct…, Kidney international. Suppl… (1998) | pd | 4 | [10.1046/j.1523-1755.1998.06736.x](https://doi.org/10.1046/j.1523-1755.1998.06736.x) | [9736279](https://www.ncbi.nlm.nih.gov/pubmed/9736279) | metadata signals extractable PD data (EC50) |
| `Godoy_2015.pdf` | Godoy AA et al., Ecotoxicological evaluation of proprano…, Ecotoxicology (London, Engl… (2015) | pd | 4 | [10.1007/s10646-015-1455-3](https://doi.org/10.1007/s10646-015-1455-3) | [25847105](https://www.ncbi.nlm.nih.gov/pubmed/25847105) | metadata signals extractable PD data (EC50) |
| `Ishizaki_1994.pdf` | Ishizaki H et al., Inhibitory effect of the nonpeptide ang…, Biochemical pharmacology (1994) | pd | 4 | [10.1016/0006-2952(94)90241-0](https://doi.org/10.1016/0006-2952(94)90241-0) | [8043024](https://www.ncbi.nlm.nih.gov/pubmed/8043024) | metadata signals extractable PD data (IC50) |
| `Ji_1995.pdf` | Ji H et al., Genetic transfer of a nonpeptide antago…, Proceedings of the National… (1995) | pd | 4 | [10.1073/pnas.92.20.9240](https://doi.org/10.1073/pnas.92.20.9240) | [7568109](https://www.ncbi.nlm.nih.gov/pubmed/7568109) | metadata signals extractable PD data (IC50) |
| `Nirula_1996.pdf` | Nirula V et al., Identification of nonconserved amino ac…, FEBS letters (1996) | pd | 4 | [10.1016/0014-5793(96)00961-1](https://doi.org/10.1016/0014-5793(96)00961-1) | [8830675](https://www.ncbi.nlm.nih.gov/pubmed/8830675) | metadata signals extractable PD data (IC50) |
| `Schupp_2006.pdf` | Schupp M et al., Regulation of peroxisome proliferator-a…, Hypertension (Dallas, Tex.… (2006) | pd | 4 | [10.1161/01.HYP.0000196946.79674.8b](https://doi.org/10.1161/01.HYP.0000196946.79674.8b) | [16365190](https://www.ncbi.nlm.nih.gov/pubmed/16365190) | metadata signals extractable PD data (EC50) |
| `Seltzer_1995.pdf` | Seltzer AM et al., Stimulation of angiotensin II AT1 recep…, Brain research (1995) | pd | 4 | [10.1016/0006-8993(95)01100-5](https://doi.org/10.1016/0006-8993(95)01100-5) | [8821729](https://www.ncbi.nlm.nih.gov/pubmed/8821729) | metadata signals extractable PD data (EC50) |
| `Spasov_2014.pdf` | Spasov AA et al., In vitro method of studying the angiote…, Bulletin of experimental bi… (2014) | pd | 4 | [10.1007/s10517-014-2705-8](https://doi.org/10.1007/s10517-014-2705-8) | [25403411](https://www.ncbi.nlm.nih.gov/pubmed/25403411) | metadata signals extractable PD data (IC50) |
| `Vanderheyden_1999.pdf` | Vanderheyden PM et al., Distinction between surmountable and in…, British journal of pharmaco… (1999) | pd | 4 | [10.1038/sj.bjp.0702398](https://doi.org/10.1038/sj.bjp.0702398) | [10193788](https://www.ncbi.nlm.nih.gov/pubmed/10193788) | metadata signals extractable PD data (EC50) |
| `Zeng_2005.pdf` | Zeng C et al., Interaction of angiotensin II type 1 an…, Hypertension (Dallas, Tex.… (2005) | pd | 4 | [10.1161/01.HYP.0000155212.33212.99](https://doi.org/10.1161/01.HYP.0000155212.33212.99) | [15699451](https://www.ncbi.nlm.nih.gov/pubmed/15699451) | metadata signals extractable PD data (EC50) |
| `Zhang_2001.pdf` | Zhang J et al., Effect of angiotensin II receptor antag…, Chinese medical sciences jo… (2001) | pd | 4 | not captured | [12901495](https://www.ncbi.nlm.nih.gov/pubmed/12901495) | metadata signals extractable PD data (EC50) |
| `Bae_2012.pdf` | Bae JW et al., Effects of CYP2C9*1/*3 and *1/*13 on th…, International journal of cl… (2012) | pgx | 8 | [10.5414/CP201467](https://doi.org/10.5414/CP201467) | [22735459](https://www.ncbi.nlm.nih.gov/pubmed/22735459) | metadata signals extractable PGX data (CYP2C9*1, PK/PD-context) |
| `Cabaleiro_2013.pdf` | Cabaleiro T et al., Evaluation of the relationship between…, Drug metabolism and disposi… (2013) | pgx | 8 | [10.1124/dmd.112.046292](https://doi.org/10.1124/dmd.112.046292) | [23118328](https://www.ncbi.nlm.nih.gov/pubmed/23118328) | metadata signals extractable PGX data (CYP2C8, PK/PD-context) |
| `Falvella_2016.pdf` | Falvella FS et al., Pharmacogenetic approach to losartan in…, Drug metabolism and persona… (2016) | pgx | 8 | [10.1515/dmpt-2016-0006](https://doi.org/10.1515/dmpt-2016-0006) | [27474842](https://www.ncbi.nlm.nih.gov/pubmed/27474842) | metadata signals extractable PGX data (CYP2C9*2, PK/PD-context) |
| `Han_2009.pdf` | Han Y et al., Effect of silymarin on the pharmacokine…, European journal of clinica… (2009) | pgx | 8 | [10.1007/s00228-009-0624-9](https://doi.org/10.1007/s00228-009-0624-9) | [19221727](https://www.ncbi.nlm.nih.gov/pubmed/19221727) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Hatta_2015.pdf` | Hatta FH et al., Differences in CYP2C9 Genotype and Enzy…, Omics : a journal of integr… (2015) | pgx | 8 | [10.1089/omi.2015.0022](https://doi.org/10.1089/omi.2015.0022) | [25977991](https://www.ncbi.nlm.nih.gov/pubmed/25977991) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `He_2011.pdf` | He SM et al., Clinical drugs undergoing polymorphic m…, Current medicinal chemistry (2011) | pgx | 8 | [10.2174/092986711794480131](https://doi.org/10.2174/092986711794480131) | [21182487](https://www.ncbi.nlm.nih.gov/pubmed/21182487) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Huang_2021.pdf` | Huang HX et al., Effect of CYP2C9 genetic polymorphism a…, Xenobiotica; the fate of fo… (2021) | pgx | 8 | [10.1080/00498254.2021.1880670](https://doi.org/10.1080/00498254.2021.1880670) | [33509019](https://www.ncbi.nlm.nih.gov/pubmed/33509019) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Kim_2016.pdf` | Kim DS et al., Effect of Red Ginseng on cytochrome P45…, Journal of ginseng research (2016) | pgx | 8 | [10.1016/j.jgr.2015.11.005](https://doi.org/10.1016/j.jgr.2015.11.005) | [27746690](https://www.ncbi.nlm.nih.gov/pubmed/27746690) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Lindamood_2011.pdf` | Lindamood C et al., Effects of commonly administered agents…, Journal of clinical pharmac… (2011) | pgx | 8 | [10.1177/0091270010370846](https://doi.org/10.1177/0091270010370846) | [20489028](https://www.ncbi.nlm.nih.gov/pubmed/20489028) | metadata signals extractable PGX data (CYP2D6, PK/PD-context) |
| `Mukai_2016.pdf` | Mukai Y et al., The Role of CYP2C8 and CYP2C9 Genotypes…, Basic & clinical pharmacolo… (2016) | pgx | 8 | [10.1111/bcpt.12520](https://doi.org/10.1111/bcpt.12520) | [26551762](https://www.ncbi.nlm.nih.gov/pubmed/26551762) | metadata signals extractable PGX data (CYP2C8, PK/PD-context) |
| `Parikh_2024.pdf` | Parikh SJ et al., Structural and biophysical analysis of…, Journal of inorganic bioche… (2024) | pgx | 8 | [10.1016/j.jinorgbio.2024.112622](https://doi.org/10.1016/j.jinorgbio.2024.112622) | [38852293](https://www.ncbi.nlm.nih.gov/pubmed/38852293) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Tanveer_2022.pdf` | Tanveer A et al., Prediction of CYP-mediated silybin A-lo…, Journal of pharmacokinetics… (2022) | pgx | 8 | [10.1007/s10928-022-09804-0](https://doi.org/10.1007/s10928-022-09804-0) | [35061161](https://www.ncbi.nlm.nih.gov/pubmed/35061161) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Yasar_2001.pdf` | Yasar U et al., The role of CYP2C9 genotype in the meta…, European journal of clinica… (2001) | pgx | 8 | [10.1007/s00228-001-0376-7](https://doi.org/10.1007/s00228-001-0376-7) | [11829203](https://www.ncbi.nlm.nih.gov/pubmed/11829203) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Bailey_2004.pdf` | Bailey DG et al., Interactions between grapefruit juice a…, American journal of cardiov… (2004) | pgx | 7 | [10.2165/00129784-200404050-00002](https://doi.org/10.2165/00129784-200404050-00002) | [15449971](https://www.ncbi.nlm.nih.gov/pubmed/15449971) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Chai_2022.pdf` | Chai YY et al., Influence of Zhuanggu Guanjie Pill on S…, Current drug metabolism (2022) | pgx | 7 | [10.2174/1389200224666221209154002](https://doi.org/10.2174/1389200224666221209154002) | [36503399](https://www.ncbi.nlm.nih.gov/pubmed/36503399) | metadata signals extractable PGX data (CYP1A2, PK/PD-context) |
| `Choi_2010.pdf` | Choi DH et al., Effects of myricetin, an antioxidant, o…, The Journal of pharmacy and… (2010) | pgx | 7 | [10.1211/jpp.62.07.0012](https://doi.org/10.1211/jpp.62.07.0012) | [20636879](https://www.ncbi.nlm.nih.gov/pubmed/20636879) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Cusinato_2019.pdf` | Cusinato DAC et al., Evaluation of potential herbal-drug int…, Journal of ethnopharmacology (2019) | pgx | 7 | [10.1016/j.jep.2019.112174](https://doi.org/10.1016/j.jep.2019.112174) | [31442620](https://www.ncbi.nlm.nih.gov/pubmed/31442620) | metadata signals extractable PGX data (CYP1A2, PK/PD-context) |
| `Daneshtalab_2006.pdf` | Daneshtalab N et al., Drug-disease interactions: losartan eff…, Journal of clinical pharmac… (2006) | pgx | 7 | [10.1177/0091270006292163](https://doi.org/10.1177/0091270006292163) | [17050800](https://www.ncbi.nlm.nih.gov/pubmed/17050800) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Guo_2012.pdf` | Guo Y et al., Repeated administration of berberine in…, European journal of clinica… (2012) | pgx | 7 | [10.1007/s00228-011-1108-2](https://doi.org/10.1007/s00228-011-1108-2) | [21870106](https://www.ncbi.nlm.nih.gov/pubmed/21870106) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Kew_2025.pdf` | Kew BM et al., Investigation of a broad-spectrum micro…, British journal of clinical… (2025) | pgx | 7 | [10.1002/bcp.70014](https://doi.org/10.1002/bcp.70014) | [39993734](https://www.ncbi.nlm.nih.gov/pubmed/39993734) | metadata signals extractable PGX data (CYP3A, PK/PD-context) |
| `Lanchote_2015.pdf` | Lanchote VL et al., Impact of visceral leishmaniasis and cu…, British journal of clinical… (2015) | pgx | 7 | [10.1111/bcp.12677](https://doi.org/10.1111/bcp.12677) | [25940755](https://www.ncbi.nlm.nih.gov/pubmed/25940755) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Luong_2021.pdf` | Luong TT et al., Pre-clinical drug-drug interaction (DDI…, Current research in toxicol… (2021) | pgx | 7 | [10.1016/j.crtox.2021.05.006](https://doi.org/10.1016/j.crtox.2021.05.006) | [34345864](https://www.ncbi.nlm.nih.gov/pubmed/34345864) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Mishima_2016.pdf` | Mishima M et al., Effects of Uric Acid on the NO Producti…, Drug research (2016) | pgx | 7 | [10.1055/s-0035-1569405](https://doi.org/10.1055/s-0035-1569405) | [26909689](https://www.ncbi.nlm.nih.gov/pubmed/26909689) | metadata signals extractable PGX data (ABCG2, PK/PD-context) |
| `Park_2019.pdf` | Park JW et al., Pharmacokinetic and haemodynamic intera…, Basic & clinical pharmacolo… (2019) | pgx | 7 | [10.1111/bcpt.13244](https://doi.org/10.1111/bcpt.13244) | [31058419](https://www.ncbi.nlm.nih.gov/pubmed/31058419) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Piscitelli_2026.pdf` | Piscitelli J et al., An Evaluation of the Drug Interaction P…, Clinical pharmacology and t… (2026) | pgx | 7 | [10.1002/cpt.70117](https://doi.org/10.1002/cpt.70117) | [41215578](https://www.ncbi.nlm.nih.gov/pubmed/41215578) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Puris_2017.pdf` | Puris E et al., A liquid chromatography-tandem mass spe…, Analytical and bioanalytica… (2017) | pgx | 7 | [10.1007/s00216-016-9994-x](https://doi.org/10.1007/s00216-016-9994-x) | [27734142](https://www.ncbi.nlm.nih.gov/pubmed/27734142) | metadata signals extractable PGX data (CYP1A2, PK/PD-context) |
| `Rowland_2018.pdf` | Rowland A et al., Evaluation of modafinil as a perpetrato…, British journal of clinical… (2018) | pgx | 7 | [10.1111/bcp.13478](https://doi.org/10.1111/bcp.13478) | [29178272](https://www.ncbi.nlm.nih.gov/pubmed/29178272) | metadata signals extractable PGX data (CYP2C19, PK/PD-context) |
| `Siu_2017.pdf` | Siu YA et al., Impact of Probe Substrate Selection on…, Drug metabolism and disposi… (2017) | pgx | 7 | [10.1124/dmd.116.073510](https://doi.org/10.1124/dmd.116.073510) | [27934636](https://www.ncbi.nlm.nih.gov/pubmed/27934636) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Treijtel_2019.pdf` | Treijtel N et al., A Cocktail Interaction Study Evaluating…, Clinical pharmacology in dr… (2019) | pgx | 7 | [10.1002/cpdd.660](https://doi.org/10.1002/cpdd.660) | [30730615](https://www.ncbi.nlm.nih.gov/pubmed/30730615) | metadata signals extractable PGX data (CYP2C19, PK/PD-context) |
| `Yang_2011.pdf` | Yang SH et al., Effects of HMG-CoA reductase inhibitors…, Pharmacology (2011) | pgx | 7 | [10.1159/000328773](https://doi.org/10.1159/000328773) | [21709429](https://www.ncbi.nlm.nih.gov/pubmed/21709429) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Yang_2016.pdf` | Yang R et al., Drug Interactions with Angiotensin Rece…, Current drug metabolism (2016) | pgx | 7 | [10.2174/1389200217666160524143843](https://doi.org/10.2174/1389200217666160524143843) | [27216792](https://www.ncbi.nlm.nih.gov/pubmed/27216792) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Zhao_2019.pdf` | Zhao Q et al., Effects of quercetin on the pharmacokin…, Xenobiotica; the fate of fo… (2019) | pgx | 7 | [10.1080/00498254.2018.1478168](https://doi.org/10.1080/00498254.2018.1478168) | [29768080](https://www.ncbi.nlm.nih.gov/pubmed/29768080) | metadata signals extractable PGX data (CYP450, PK/PD-context) |
| `Zheng_2020.pdf` | Zheng YF et al., Lack of Correlation between In Vitro an…, Pharmaceutics (2020) | pgx | 7 | [10.3390/pharmaceutics12040328](https://doi.org/10.3390/pharmaceutics12040328) | [32272615](https://www.ncbi.nlm.nih.gov/pubmed/32272615) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Arslanbekova_2013.pdf` | Arslanbekova SM et al., [Relationship between warfarin dosing a…, Kardiologiia (2013) | pgx | 5 | not captured | [24800477](https://www.ncbi.nlm.nih.gov/pubmed/24800477) | metadata signals extractable PGX data (CYP2C9) |
| `Byeon_2016.pdf` | Byeon JY et al., Effects of ABCB1 Genetic Polymorphism o…, Clinical therapeutics (2016) | pgx | 5 | [10.1016/j.clinthera.2016.07.139](https://doi.org/10.1016/j.clinthera.2016.07.139) | [27673635](https://www.ncbi.nlm.nih.gov/pubmed/27673635) | metadata signals extractable PGX data (ABCB1) |
| `Chen_2014.pdf` | Chen SZ et al., Drug-drug interaction of losartan and g…, International journal of cl… (2014) | pgx | 5 | [10.5414/CP202071](https://doi.org/10.5414/CP202071) | [24986093](https://www.ncbi.nlm.nih.gov/pubmed/24986093) | metadata signals extractable PGX data (CYP2C9*1) |
| `Eadon_2022.pdf` | Eadon MT et al., Pharmacogenomics of Hypertension in CKD…, Kidney360 (2022) | pgx | 5 | [10.34067/kid.0005362021](https://doi.org/10.34067/kid.0005362021) | [35342886](https://www.ncbi.nlm.nih.gov/pubmed/35342886) | metadata signals extractable PGX data (CYP2C9) |
| `Lajer_2007.pdf` | Lajer M et al., CYP2C9 variant modifies blood pressure-…, Diabetic medicine : a journ… (2007) | pgx | 5 | [10.1111/j.1464-5491.2007.02086.x](https://doi.org/10.1111/j.1464-5491.2007.02086.x) | [17305793](https://www.ncbi.nlm.nih.gov/pubmed/17305793) | metadata signals extractable PGX data (CYP2C9) |
| `Thu_2016.pdf` | Thu OK et al., Effect of commercial Rhodiola rosea on…, European journal of clinica… (2016) | pgx | 5 | [10.1007/s00228-015-1988-7](https://doi.org/10.1007/s00228-015-1988-7) | [26613955](https://www.ncbi.nlm.nih.gov/pubmed/26613955) | metadata signals extractable PGX data (CYP1A2) |

<sub>queue written 2026-09-30T18:09:48.462308+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PD | Ahad_2020 | not_relevant | 2 | 0 | SBP effects and losartan PK are reported separately, but no numeric losartan exposure- or dose-response relationship or derivable PD parameters are provided. |
| PD | Ahad_2022 | not_relevant | 2 | 1 | Reports group-level blood-pressure changes and losartan exposure changes, but no analyzed or derivable exposure-effect relationship or numeric PD parameters. |
| PD | Alnajjar_2020 | not_relevant | 0 | 0 | Losartan is evaluated by docking, but no losartan exposure- or dose-response relationship or numeric PD parameters are reported; the stated IC50 is for olmesartan. |
| PD | Anderson_2009 | not_relevant | 1 | 0 | This review-style summary mentions renal effects of losartan but reports no dose-response relationship or numeric PD parameters. |
| popPK | Angeli_2018 | irrelevant | 0 | 0 | This review concerns fimasartan and reports no quantitative disposition parameters for losartan. |
| PD | Angeli_2018 | not_relevant | 0 | 0 | This review discusses fimasartan, mentioning losartan only as a structural predecessor; it reports no losartan exposure- or dose-response relationship or numeric PD parameters. |
| PGx | Arslanbekova_2013 | not_relevant | 0 | 0 | E-3174 is used as a CYP2C9 activity marker to predict warfarin dose; the paper does not report a genotype effect on losartan pharmacokinetics or pharmacodynamics. |
| popPK | Asiedu-Gyekye_2003 | irrelevant | 1 | 0 | Losartan is administered in a cerebral vascular-exchange study, but no losartan pharmacokinetic parameters or values are reported. |
| popPK | Azizi_1999 | irrelevant | 1 | 0 | Losartan is a comparator, and no quantitative disposition parameters are reported. |
| PD | Azizi_1999 | not_relevant | 3 | 2 | The study reports a correlation between EXP 3174 exposure and renin AUC (r=0.65), but gives no effect-versus-concentration curve or derivable PD parameter; losartan was tested at only one dose. |
| popPK | Baan_1998 | irrelevant | 0 | 0 | This is a forearm pharmacodynamic study and reports no losartan disposition parameters or PK model values. |
| popPK | Baan_1998_2 | irrelevant | 0 | 0 | Losartan is used as a pharmacodynamic antagonist, and no losartan disposition parameters are reported. |
| popPK | Baan_1999 | irrelevant | 0 | 0 | This is an isolated-tissue pharmacology study and reports no losartan disposition parameters or numeric PK values. |
| PD | Baan_1999 | not_relevant | 3 | 3 | Losartan was tested at only one concentration; the paper reports an arterial Emax reduction but no losartan concentration-response curve or numeric exposure-response parameter. |
| PD | Bacal_1994 | not_relevant | 1 | 0 | Losartan is mentioned as a single-condition antagonist in an n=4 experiment, but no concentration-response or dose-response curve or numeric PD parameters are reported or derivable. |
| popPK | Baek_2013 | relevant | 9 | 0 | Losartan is a dog PK subject with a two-compartment model, but no numeric parameter values are shown in the provided evidence. |
| PD | Bai_2012 | not_relevant | 2 | 0 | Losartan is mentioned only as a qualitative in-vivo potency comparator; no numeric dose/exposure-response parameters for losartan are stated or derivable. |
| PGx | Bailey_2004 | not_relevant | 0 | 0 | The text discusses a grapefruit juice interaction with losartan, not an effect of a gene variant, genotype, or phenotype. |
| PGx | Balcerac_2026 | not_relevant | 0 | 0 | The study examines a PPARγ variant’s association with radiation-induced leukoencephalopathy, not its effect on a losartan pharmacokinetic or pharmacodynamic parameter. |
| popPK | Batra_1999 | irrelevant | 0 | 0 | Losartan is only an antagonist in a cell study, and no losartan pharmacokinetic values are reported. |
| PD | Batra_1999 | not_relevant | 2 | 0 | Losartan is mentioned only as an AT1 antagonist that failed to affect pneumadin-evoked responses; no losartan exposure- or dose-response relationship or numeric PD parameters are reported. |
| PGx | Bedada_2018 | not_relevant | 0 | 0 | Losartan was used as a CYP2C9 probe, but the reported genotype-dependent effects involved CYP1A2 and CYP2C19, not losartan metabolism. |
| PD | Bhunia_2017_2 | not_relevant | 0 | 0 | Losartan is mentioned only as a ligand known to bind a site; no losartan dose- or exposure-response relationship or PD parameters are reported. |
| popPK | Briand_1994 | irrelevant | 0 | 0 | Losartan is only an antagonist in a cell-based receptor study, with no pharmacokinetic disposition parameters reported. |
| popPK | Castro-Chaves_2006 | irrelevant | 0 | 0 | Losartan is used only as an angiotensin-II receptor antagonist, and no losartan pharmacokinetic parameters are reported. |
| PD | Castro-Chaves_2006 | not_relevant | 2 | 0 | Losartan is tested at a single concentration and is reported to completely block angiotensin-II effects, but no losartan exposure- or dose-response relationship or numeric PD parameter is reported. |
| popPK | Catalioto_1995 | irrelevant | 0 | 0 | Losartan is a pharmacodynamic comparator in a cell study, with no disposition parameters reported. |
| PGx | Chai_2022 | not_relevant | 0 | 0 | The paper assesses herbal-treatment effects on CYP activity, not effects of a gene variant, genotype, or phenotype on losartan PK/PD. |
| popPK | Chan_2014 | irrelevant | 0 | 0 | Losartan is only an AT1R antagonist in a mechanistic study, with no losartan disposition parameters reported. |
| PD | Chan_2014 | not_relevant | 2 | 0 | Losartan is reported to suppress responses qualitatively, but no losartan exposure-response curve or numeric PD parameter is stated or derivable. |
| PGx | Choi_2010 | not_relevant | 0 | 0 | The study evaluates myricetin-mediated drug interactions in rats, not effects of a gene variant, genotype, or phenotype on losartan PK/PD. |
| PGx | Christensen_2026 | not_relevant | 0 | 0 | The text reports losartan among medications implicated in drug–gene interactions but gives no genotype-specific change in a pharmacokinetic or pharmacodynamic parameter. |
| PD | Cirillo_1995 | not_relevant | 0 | 0 | not captured |
| popPK | Coelho_2020 | irrelevant | 1 | 0 | Losartan is only a phenotyping probe, and no numerical losartan disposition parameters are reported in the provided evidence. |
| PGx | Coelho_2020 | not_relevant | 0 | 0 | The study did not model losartan or report a genotype/phenotype effect on a losartan PK or PD parameter. |
| PD | Costa-Conceicao_2026 | not_relevant | 0 | 0 | Losartan is listed as an exposure, but no losartan-specific effect results or numeric exposure-response relationship are reported. |
| popPK | Cozzoli_2014 | irrelevant | 0 | 0 | Losartan is only used as an antagonist, and no losartan pharmacokinetic parameters are reported. |
| PD | Cozzoli_2014 | not_relevant | 2 | 0 | The reported EC50 is for angiotensin II; losartan is only described as blocking its effects, with no numeric losartan exposure- or dose-response parameters. |
| popPK | Cullinane_2002 | irrelevant | 0 | 0 | Losartan is only an antagonist in a cell-function study, with no losartan disposition parameters reported. |
| PD | Cullinane_2002 | not_relevant | 2 | 0 | Losartan is tested at a single concentration and described as significantly blocking AII effects, but no losartan concentration-response or dose-response relationship or quantitative effect magnitude is reported. |
| PGx | Cusinato_2019 | not_relevant | 0 | 0 | The paper reports a propolis–losartan interaction, not an effect of a gene variant, genotype, or phenotype on losartan PK/PD. |
| PGx | Daneshtalab_2006 | not_relevant | 2 | 2 | The paper speculates that one subject’s undetectable EXP 3174 may reflect insufficient CYP2C9 activity, but reports no genotype or defined pharmacogenomic phenotype effect. |
| popPK | Dias_2022 | irrelevant | 0 | 0 | Losartan is a comparator treatment, and no losartan pharmacokinetic parameters or values are reported. |
| PD | Dias_2022 | not_relevant | 1 | 0 | Losartan was given at one fixed dose; the reported Emax is for Ca2+-induced vascular responses, not a losartan exposure- or dose-response relationship. |
| popPK | Dickinson_1994 | irrelevant | 0 | 0 | This is a receptor-pharmacology comparison and reports no losartan pharmacokinetic disposition parameters. |
| PGx | Eadon_2022 | not_relevant | 0 | 0 | The paper does not report a losartan-specific pharmacokinetic or pharmacodynamic effect of a gene variant or genotype. |
| PD | Eads_2020 | not_relevant | 0 | 0 | The article discusses NDMA contamination and pharmacists’ general expertise, but reports no losartan dose- or exposure-response relationship or numeric PD parameters. |
| PGx | Elkiran_2007 | not_relevant | 0 | 0 | The study reports a chemotherapy-associated change in CYP2C9 activity measured with losartan, not an effect of a gene variant, genotype, or phenotype. |
| popPK | Elmfeldt_2002 | irrelevant | 0 | 0 | This is a dose-response study of blood-pressure effects and reports no losartan pharmacokinetic parameters. |
| PGx | Falvella_2016 | not_relevant | 2 | 8 | CYP2C9 poor metabolizers had a higher median tolerated dose, but the study reports no genotype-associated PK or PD parameter. |
| popPK | Fernandes_2005 | irrelevant | 0 | 0 | Losartan is only a receptor antagonist in a venoconstriction study, with no pharmacokinetic parameters reported. |
| PD | Fernandes_2005 | not_relevant | 2 | 0 | Losartan is tested at a single, unspecified exposure; the reported EC50 shift is for Ang II, not a losartan exposure- or dose-response relationship. |
| popPK | Fernandes_2025 | irrelevant | 0 | 0 | This is an adsorption and ecotoxicity study, not a pharmacokinetic study of losartan. |
| PD | Fernandes_2025 | not_relevant | 0 | 0 | The study evaluates losartan adsorption and environmental ecotoxicity, not a pharmacodynamic or exposure-response relationship for the drug. |
| popPK | Filipeanu_2001 | irrelevant | 0 | 0 | Losartan is used as a receptor antagonist in a cell-growth study, with no losartan pharmacokinetic parameters reported. |
| PD | Filipeanu_2001 | not_relevant | 2 | 1 | Losartan is tested only at a single concentration (1 μM); the reported Emax change is for the Angiotensin II response, not a losartan exposure- or dose-response relationship. |
| PD | Fior_1994 | not_relevant | 2 | 0 | Losartan is reported to block the interaction, but no losartan dose- or concentration-response relationship or numeric losartan PD parameter is stated or derivable. |
| popPK | Gauthier_2008 | irrelevant | 0 | 0 | Losartan is used as a receptor antagonist, with no losartan pharmacokinetic parameters reported. |
| PD | Gauthier_2008 | not_relevant | 0 | 0 | Losartan was tested at a single concentration; the reported EC50 and maximum effects describe Ang II responses, not a losartan exposure- or dose-response relationship. |
| PD | Ghumman_2023 | not_relevant | 2 | 0 | The text qualitatively compares antihypertensive effects and mentions a low-dose formulation, but reports no extractable dose- or concentration-effect relationship or numeric PD parameters. |
| popPK | Gloy_1998 | irrelevant | 0 | 0 | no_text gate: only 56 chars of text extracted (&lt; 400) |
| PD | Gloy_1998 | not_relevant | 2 | 0 | Losartan is used as a receptor blocker, but the paper does not report an extractable losartan dose- or concentration-response relationship or numeric PD parameters. |
| popPK | Godoy_2015 | irrelevant | 0 | 0 | This is an aquatic ecotoxicity study, not a pharmacokinetic study, and reports no losartan disposition parameters. |
| PD | Godoy_2015 | not_relevant | 2 | 0 | The text describes losartan ecotoxicity testing, but gives no numeric losartan exposure-response parameter or curve; the stated EC50 is for propranolol. |
| popPK | Goebel_2010 | irrelevant | 0 | 0 | Losartan is only a structural inspiration; no losartan pharmacokinetic parameters or numeric values are reported. |
| PD | Goebel_2010 | not_relevant | 0 | 0 | Losartan is mentioned only as structural inspiration; no losartan exposure- or dose-response relationship or PD parameters are reported. |
| popPK | Gradman_2002 | irrelevant | 0 | 0 | This is a pharmacology review, not a losartan PK study, and Table 1’s referenced values are not provided. |
| PD | Gradman_2002 | not_relevant | 2 | 0 | Review qualitatively describes losartan's surmountable antagonism, but provides no numeric losartan PD parameters or extractable dose/concentration-effect curve. |
| PGx | Guo_2012 | not_relevant | 0 | 0 | Reports CYP inhibition by berberine, not a gene variant, genotype, or phenotype effect on losartan PK/PD. |
| PGx | Hansson_1995 | not_relevant | 0 | 0 | The ACE gene polymorphism is mentioned in relation to coronary heart disease risk, not an effect on losartan pharmacokinetics or pharmacodynamics. |
| PGx | He_2011 | not_relevant | 0 | 0 | The text mentions losartan as a CYP2C9 substrate but reports no genotype-specific effect on its PK or PD parameters. |
| PGx | Hjelmesæth_2018 | not_relevant | 0 | 0 | This is a study protocol that plans to measure losartan drug:metabolite ratios and genotypic variation, but reports no genotype-specific pharmacokinetic effects. |
| popPK | Holmgren_1998 | irrelevant | 0 | 0 | This is an in-vitro pharmacology study with no losartan disposition parameters or numeric PK values. |
| PGx | Inui_2013 | not_relevant | 0 | 0 | The paper evaluates rifampicin-related changes in CYP activity using losartan as a probe, not the effect of a gene variant, genotype, or phenotype on losartan PK/PD. |
| popPK | Ishihata_1993 | irrelevant | 0 | 0 | Losartan is used as a receptor antagonist, and no pharmacokinetic parameters or values are reported. |
| PD | Ishihata_1993 | not_relevant | 2 | 0 | Losartan is reported to inhibit the AII-induced effects, but no quantitative losartan concentration-effect relationship or numeric PD parameter is stated or derivable. |
| popPK | Ishizaki_1994 | irrelevant | 0 | 0 | This in-vitro PDE inhibition study reports no losartan pharmacokinetic disposition parameters. |
| popPK | Jiang_2000 | irrelevant | 0 | 0 | Losartan is used only as an antagonist, and no losartan pharmacokinetic parameters are reported. |
| PD | Jiang_2000 | not_relevant | 2 | 0 | Losartan was tested at a single concentration (10 nM) and qualitatively inhibited Ang II-induced contraction; no losartan dose/concentration-response or numeric PD effect is reported. |
| popPK | Juarez_2017 | irrelevant | 0 | 0 | Losartan is used as a receptor antagonist in a vascular study, with no pharmacokinetic parameters reported. |
| PD | Juarez_2017 | not_relevant | 1 | 0 | Losartan is used as a fixed antagonist condition, but no losartan dose/concentration-response or numeric losartan PD parameters are reported or derivable. |
| popPK | Kamal_2017 | irrelevant | 0 | 0 | Losartan is used only as an AT1-receptor antagonist, and no losartan pharmacokinetic parameters are reported. |
| PD | Kamal_2017 | not_relevant | 0 | 0 | Losartan is mentioned only as an AT1-receptor blocker; the reported calcium dose-response and EC50 values are for AngII, with no numeric losartan exposure- or dose-response relationship. |
| popPK | Karatza_2020 | relevant | 10 | 0 | The paper reports a population-PK model for losartan, but no numeric parameter values appear in the provided evidence. |
| popPK | Karatza_2021 | relevant | 10 | 0 | Losartan is the subject of population-PK models, but no numeric parameter values are provided in the evidence. |
| PD | Kariv_2001 | not_relevant | 0 | 0 | The paper measures losartan plasma protein binding to validate an assay and reports no pharmacodynamic or exposure-response relationship. |
| PD | Keiser_1995 | not_relevant | 0 | 0 | The numeric dose- and concentration-response results are for CI-996; no losartan-specific PD relationship or parameters are reported. |
| PGx | Kew_2025 | not_relevant | 0 | 0 | The paper investigates micronutrient–drug interactions, not genetic effects on losartan pharmacokinetics or pharmacodynamics. |
| PD | Kg_2026 | not_relevant | 0 | 0 | Losartan is assessed at a single treatment regimen with behavioral outcomes, but no dose- or exposure-response analysis or numeric PD parameters are reported or derivable. |
| popPK | Khandave_2012 | relevant | 7 | 1 | This is an original human losartan PK study, but the provided evidence contains no numeric parameter values. |
| PGx | Kim_2016 | not_relevant | 0 | 0 | The paper examines red ginseng effects on CYP450 and P-glycoprotein activity, not genotype- or phenotype-associated effects on losartan. |
| popPK | Kitamura_2007 | irrelevant | 0 | 0 | This is a glucose-outcomes study, not a losartan pharmacokinetic study, and reports no losartan disposition parameters. |
| PGx | Kvitne_2022 | not_relevant | 0 | 0 | The paper evaluates effects of T2DM and obesity, not genetic variants, genotypes, or phenotypes, and reports no change in CYP2C9 activity for losartan. |
| PGx | Lanchote_2015 | not_relevant | 0 | 0 | The paper examines disease and chemotherapy effects on CYP activity, not a gene variant, genotype, or pharmacogenomic phenotype effect on losartan. |
| PD | Leifert_2009 | not_relevant | 2 | 0 | Losartan is mentioned only as an example; no losartan-specific concentration-effect data or numeric PD parameters are reported or derivable. |
| popPK | Li_1995 | irrelevant | 0 | 0 | Losartan is used as a receptor antagonist in an aorta study, with no losartan pharmacokinetic parameters reported. |
| PD | Li_1995 | not_relevant | 3 | 2 | Losartan caused concentration-dependent rightward shifts and was assessed by Schild analysis, but no numeric Schild slope, dose ratios, or potency estimate is stated or derivable from the provided text. |
| popPK | Li_1998 | irrelevant | 0 | 0 | The paper reports vascular pharmacology, not losartan disposition parameters, and provides no numeric PK values. |
| popPK | Li_2000 | irrelevant | 0 | 0 | Losartan is only a pharmacological comparator, and no losartan PK parameters or numeric values are reported. |
| PD | Li_2000 | not_relevant | 3 | 2 | Losartan is only mentioned in a relative potency comparison (irbesartan is twofold more potent); no losartan-specific concentration-effect curve or numeric PD parameter is reported or derivable. |
| popPK | Lill_2000 | irrelevant | 0 | 0 | Losartan is only listed as a concomitant interacting medication; the reported pharmacokinetic values are for cyclosporine. |
| PGx | Lindamood_2011 | not_relevant | 0 | 0 | The paper reports no drug interaction with losartan and does not describe a genetic effect on any losartan PK or PD parameter. |
| PD | Luong_2021 | not_relevant | 0 | 0 | The title indicates a preclinical drug–drug interaction study, not a losartan dose- or exposure–response analysis with numeric PD parameters. |
| PGx | Luong_2021 | not_relevant | 0 | 0 | The paper describes preclinical drug–drug interactions, not a gene variant, genotype, or phenotype effect on losartan PK or PD. |
| popPK | Magalhães_2016 | irrelevant | 2 | 8 | Numeric losartan AUC and half-life values appear in the table, but no clearance, volume, or compartmental/population-PK model is reported. |
| PD | Magalhães_2016 | not_relevant | 0 | 0 | The study reports losartan and metabolite pharmacokinetics and metabolic ratios, but no pharmacodynamic endpoint or exposure-/dose-response analysis; it explicitly notes no relevant pharmacodynamic interactions. |
| PGx | Magalhães_2016 | not_relevant | 0 | 0 | The study evaluates drug–drug interactions in rats, not effects of a gene variant, genotype, or phenotype on losartan PK or PD. |
| popPK | Marchetti_2003 | irrelevant | 0 | 0 | Losartan is used only as an AT1-receptor blocker; no losartan disposition parameters are reported. |
| PD | Marchetti_2003 | not_relevant | 1 | 0 | Losartan is mentioned only as blocking the ANG I response; no losartan dose/concentration-effect relationship or numeric PD parameters are reported. |
| PGx | Mishima_2016 | not_relevant | 0 | 0 | The study reports losartan’s effect on urate-related cellular responses, not a gene variant/genotype/phenotype effect on a losartan PK or PD parameter. |
| PD | Miyazawa_1996 | not_relevant | 0 | 0 | Losartan is mentioned only as a reference compound; no losartan-specific dose/exposure-response data or numeric PD parameters are reported. |
| PGx | Mukai_2016 | not_relevant | 0 | 0 | The study examines genotype-dependent inhibition of paclitaxel metabolism by losartan, not a genetic effect on losartan’s PK or PD parameters. |
| popPK | Murali_2014 | irrelevant | 0 | 0 | Losartan is used only as an AT1 receptor blocker; no losartan pharmacokinetic parameters or numeric values are reported. |
| PD | Murali_2014 | not_relevant | 2 | 0 | Losartan is tested only as a single-concentration blocker (1 μm); the reported EC50 is for ANG II, with no losartan exposure-response relationship or numeric PD parameters. |
| popPK | Neves_2008 | irrelevant | 2 | 1 | This bioequivalence study reports AUC and Cmax, but no quantitative disposition parameters for losartan. |
| PD | Nie_2012 | not_relevant | 0 | 0 | Losartan is mentioned only as an acute-toxicity comparator; no losartan dose- or exposure-response relationship or PD parameters are reported. |
| popPK | Niles_2016 | irrelevant | 0 | 0 | Losartan is a treatment, and no pharmacokinetic parameters or numeric PK values are reported. |
| PD | Nirula_1996 | not_relevant | 2 | 0 | Reports only qualitative relative IC50/affinity changes for receptor binding; no numeric losartan PD parameter or concentration-effect curve is provided. |
| PD | Nirula_1996_2 | not_relevant | 0 | 0 | The paper concerns AT1-receptor binding-site characterization, not a losartan concentration- or dose-response for a pharmacodynamic effect. |
| PGx | Niu_2022 | not_relevant | 0 | 0 | The paper reports SMI-related herb–drug effects on losartan pharmacokinetics, but does not assess gene variants, genotypes, or phenotypes. |
| PD | Ogura_2025 | not_relevant | 1 | 0 | The study compares adverse-event reporting proportions across ARBs and provides no losartan dose- or exposure-response analysis or extractable numeric PD parameters. |
| PGx | Parikh_2024 | not_relevant | 1 | 0 | The paper examines CYP2C9 variants structurally and biophysically, but does not report a losartan PK or PD parameter effect. |
| PGx | Park_2019 | not_relevant | 0 | 0 | Reports an amlodipine–losartan drug interaction, not a gene variant, genotype, or phenotype effect on losartan PK/PD. |
| popPK | Peiró_1997 | irrelevant | 0 | 0 | Losartan is studied for its effects on cell proliferation, with no pharmacokinetic parameters or values reported. |
| PD | Peiró_1997 | not_relevant | 1 | 0 | Losartan was tested only at 10 µM and reportedly did not alter the measured outcomes; no exposure- or dose-response relationship or numeric PD parameters are reported or derivable. |
| PGx | Peyriere_2012 | not_relevant | 0 | 0 | The review discusses drug interactions involving losartan but reports no gene variant, genotype, or phenotype effects on its PK or PD parameters. |
| PGx | Piscitelli_2026 | not_relevant | 0 | 0 | The paper evaluates a drug interaction, not a genetic or phenotypic effect on losartan PK/PD. |
| popPK | Poggioli_1992 | irrelevant | 0 | 0 | Losartan is only an experimental receptor antagonist, with no pharmacokinetic parameters or numeric disposition values reported. |
| PD | Poggioli_1992 | not_relevant | 2 | 0 | Losartan is reported only to inhibit ANG II effects qualitatively; no losartan exposure- or dose-response data or numeric PD parameters are provided. |
| PGx | Puris_2017 | not_relevant | 0 | 0 | Losartan is included as a CYP2C9 probe, but the paper reports no genetic variation or pharmacogenomic effect on its PK or PD parameters. |
| PD | Qu_2020 | not_relevant | 5 | 1 | The text describes losartan concentration-response IC50 and Schild analyses, but provides no numeric values or effect-versus-concentration curve to extract. |
| popPK | Reid_1993 | irrelevant | 0 | 0 | Losartan is mentioned only for blood-pressure effects, with no losartan PK parameter values provided. |
| PD | Reid_1993 | not_relevant | 3 | 0 | Losartan is described as causing dose-related blood-pressure falls, but no numeric PD parameters or extractable concentration/effect curve are reported. |
| popPK | Reque_2021 | irrelevant | 0 | 0 | This is an ecotoxicity study and reports no losartan pharmacokinetic parameters. |
| PGx | Rowland_2018 | not_relevant | 0 | 0 | The protocol concerns modafinil-mediated drug interactions and reports no gene-related effect on losartan PK or PD. |
| popPK | Rump_1995 | irrelevant | 0 | 0 | Losartan’s active metabolite EXP 3174 is used only as a receptor antagonist; no losartan disposition parameters are reported. |
| popPK | Saris_2000 | irrelevant | 0 | 0 | Losartan is only an administered receptor antagonist, and no losartan disposition parameters are reported; the numeric infusion rate is a dose, not a PK value. |
| PD | Saris_2000 | not_relevant | 1 | 0 | Losartan is mentioned only as a single-dose antagonist that inhibited Ang II effects; no losartan exposure- or dose-response relationship or numeric PD parameters are reported or derivable. |
| popPK | Schupp_2006 | irrelevant | 0 | 0 | no_text gate: only 95 chars of text extracted (&lt; 400) |
| popPK | Selamet_2018 | irrelevant | 0 | 0 | The paper reports clinical outcomes of losartan treatment, not losartan pharmacokinetic parameters. |
| popPK | Seltzer_1995 | irrelevant | 0 | 0 | Losartan is used only as an AT1 antagonist; no losartan pharmacokinetic parameters or values are reported. |
| PD | Seltzer_1995 | not_relevant | 2 | 0 | Losartan is tested only at a single concentration (10 µM) and qualitatively reported to antagonize the angiotensin II response; the reported EC50 (2.7 nM) is for angiotensin II, not losartan. |
| PGx | Senda_2017 | not_relevant | 0 | 0 | The study measures losartan inhibition of arachidonic acid metabolism in vitro, but reports no genetic variation effect on losartan PK or PD. |
| popPK | Shah_1999 | irrelevant | 0 | 0 | Losartan is only used as an antagonist in a cell study, with no losartan disposition parameters reported. |
| PD | Shah_1999 | not_relevant | 1 | 0 | Losartan is only reported qualitatively to block some angiotensin II effects; no losartan dose/concentration-response or numeric PD parameters are stated or derivable. |
| PD | Shams_2010 | not_relevant | 2 | 0 | Reports a single blood-pressure reduction (25.42%) and duration after patch treatment, but no dose- or exposure-response analysis or derivable PD parameters. |
| popPK | Shimizu_2012 | relevant | 9 | 0 | The study reports population PK analysis of losartan in rats, but no numeric parameter values are provided in the evidence. |
| PD | Sica_1995 | not_relevant | 1 | 0 | Blood pressure and pulse were measured, but no pharmacodynamic results or exposure-/dose-response relationship is reported. |
| PD | Sica_2000 | not_relevant | 2 | 0 | Reports qualitative biomarker changes after fixed-dose losartan, but no numeric exposure- or dose-response relationship or derivable PD parameters. |
| PGx | Siu_2017 | not_relevant | 0 | 0 | The paper concerns CYP reaction phenotyping methods and does not report a genetic effect on a losartan PK or PD parameter. |
| PD | Spasov_2014 | not_relevant | 2 | 0 | The text says IC50 values were calculated over a concentration range, but provides no numeric IC50 values or effect-versus-concentration data to extract. |
| PGx | Stearns_1995 | not_relevant | 0 | 0 | The paper identifies CYP enzymes involved in losartan metabolism but reports no effect of a gene variant, genotype, or phenotype on a PK/PD parameter. |
| popPK | Suh_1992 | irrelevant | 0 | 0 | Losartan is only used as an antagonist in a cell study, with no losartan pharmacokinetic parameters reported. |
| PD | Suh_1992 | not_relevant | 1 | 0 | Losartan is reported only to inhibit effects of [Sar1]angiotensin II; no losartan concentration- or dose-response or numeric losartan PD parameter is stated or derivable. |
| PGx | Tayag_2023 | not_relevant | 0 | 0 | The paper examines 5-FU co-administration and blood pressure, but reports no gene variant, genotype, or phenotype effect on losartan PK or PD. |
| PGx | Theken_2012 | not_relevant | 0 | 0 | No gene variant/genotype/phenotype effect on a losartan pharmacokinetic or pharmacodynamic parameter is reported. |
| popPK | Touyz_1999 | irrelevant | 0 | 0 | Losartan is only an in-vitro receptor antagonist, and no pharmacokinetic parameters are reported. |
| PD | Touyz_1999 | not_relevant | 2 | 0 | Losartan is tested only at a fixed concentration as an antagonist, with qualitative blockade reported; no losartan dose- or exposure-response relationship or numeric PD parameters are provided. |
| PGx | Treijtel_2019 | not_relevant | 0 | 0 | The study evaluates drug–drug interactions with ASP8477 and does not report a genetic or phenotypic effect on losartan PK/PD. |
| popPK | Van_2020 | irrelevant | 1 | 0 | This is a pharmacogenetic efficacy study, not a losartan PK study, and no losartan disposition parameter values are reported. |
| PGx | Van_2020 | not_relevant | 0 | 10 | The study reports no difference in losartan response by CYP2C9 metabolizer status and does not report a losartan PK parameter. |
| popPK | Vanderheyden_1999 | irrelevant | 0 | 0 | no_text gate: only 155 chars of text extracted (&lt; 400) |
| PGx | Varshney_2019 | not_relevant | 0 | 0 | The study uses losartan as a CYP2C9 probe but does not report genotype- or phenotype-associated changes in its PK or PD parameters. |
| PGx | Wang_2016 | not_relevant | 0 | 0 | Reports apigenin-mediated in vitro inhibition of losartan metabolism, not an effect of a gene variant, genotype, or phenotype. |
| popPK | Washburn_2001 | irrelevant | 0 | 0 | Losartan is only used as a receptor antagonist in an electrophysiology study, with no losartan pharmacokinetic parameters reported. |
| PD | Washburn_2001 | not_relevant | 2 | 1 | Losartan was tested only at 1 µM, with a reported residual angiotensin effect; no losartan exposure- or dose-response curve or numeric PD parameter can be derived. |
| PGx | Xiao_2023 | not_relevant | 0 | 0 | The paper uses losartan as a reference drug but reports no gene variant, genotype, or phenotype effect on its PK or PD. |
| PGx | Yang_2011 | not_relevant | 0 | 0 | The paper reports a simvastatin–losartan drug interaction in rats, not an effect of a gene variant, genotype, or phenotype. |
| PGx | Yang_2011_2 | not_relevant | 0 | 0 | The study reports a ticlopidine drug interaction in rats, not an effect of a gene variant, genotype, or phenotype on losartan PK/PD. |
| PGx | Yang_2016 | not_relevant | 0 | 0 | This review discusses CYP-mediated drug interactions, not effects of gene variants, genotypes, or phenotypes on losartan PK or PD parameters. |
| PGx | Yasar_2001 | not_relevant | 0 | 0 | Losartan is mentioned only in a comparison of metabolite ratios; the paper reports no genotype effect on a losartan PK or PD parameter. |
| PGx | Yasar_2002 | not_relevant | 1 | 0 | The title describes within-person variability in a urinary losartan oxidation marker, not an effect of a gene variant, genotype, or phenotype on a PK/PD parameter. |
| popPK | Ytterberg_2001 | irrelevant | 0 | 0 | Losartan is used as a receptor antagonist, and no losartan pharmacokinetic parameters or values are reported. |
| PD | Ytterberg_2001 | not_relevant | 2 | 0 | Losartan is reported to cause a dose-dependent rightward shift of the Ang II response, but no losartan dose levels or numeric effect parameters are provided or derivable. |
| popPK | Zeng_2005 | irrelevant | 0 | 0 | Losartan is only an AT1 receptor antagonist in a cell study, with no losartan pharmacokinetic parameters reported. |
| PD | Zeng_2005 | not_relevant | 2 | 0 | Losartan is only reported to block the angiotensin II effect; the numeric concentration-response parameters are for angiotensin II, not losartan. |
| PGx | Zhan_2023 | not_relevant | 0 | 0 | The study measures vortioxetine-mediated CYP2C9 inhibition of losartan metabolism in vitro, not a gene variant, genotype, or phenotype effect on losartan PK or PD. |
| popPK | Zhang_2001 | irrelevant | 0 | 0 | This is a pharmacology study, not a losartan PK study, and no losartan disposition parameters are reported. |
| PD | Zhang_2001 | not_relevant | 2 | 0 | Losartan was tested at a single dose; the reported group effects do not define a losartan dose/exposure-response relationship, and the EC50 is for SNP, not losartan. |
| PGx | Zhao_2019 | not_relevant | 0 | 0 | Reports a quercetin–losartan drug interaction in rats, not an effect of a gene variant, genotype, or phenotype. |
| PD | Zhao_2024 | not_relevant | 0 | 0 | Losartan is mentioned only as a fixed-dose comparator; no losartan exposure- or dose-response relationship or numeric PD parameters are reported or derivable. |
| PD | Zheng_2014 | not_relevant | 0 | 0 | Losartan is mentioned only for an LD50 comparison; the reported dose-response and blood-pressure effects are for compound 1. |
| PGx | Zheng_2020 | not_relevant | 0 | 0 | The paper studies sophoranone’s CYP2C9 inhibition, not how a genetic variant or phenotype affects a losartan PK/PD parameter. |
| popPK | Zhou_2003 | irrelevant | 0 | 0 | Losartan is only an antagonist in a vascular-response experiment; no losartan PK parameters are reported. |
| PD | Zhou_2003 | not_relevant | 2 | 1 | Losartan is tested only at a single concentration (10 μM), with complete inhibition reported; no losartan exposure-response relationship or numeric PD parameters are provided or derivable. |
| PD | da_2026 | not_relevant | 2 | 0 | Losartan is mentioned only in potential drug-interaction counts; no dose- or exposure-response analysis or numeric PD parameters are reported. |
| PD | de_2024 | not_relevant | 2 | 0 | Losartan is reported to reverse nitrite-induced tolerance, but no losartan dose/concentration-response analysis or numeric PD parameters are provided. |
| popPK | dos_2006 | irrelevant | 0 | 0 | Losartan is used as a vascular antagonist, and no losartan pharmacokinetic parameters are reported. |
| PD | dos_2006 | not_relevant | 2 | 0 | Losartan was tested at a single concentration (100 µM); its qualitative effect on phenylephrine Emax is noted, but no losartan exposure-response curve or numeric PD parameter is reported or derivable. |
| PD | von_2021 | not_relevant | 3 | 0 | The text says losartan IC50 determinations were performed, but gives no numeric IC50, effect-concentration curve, or data from which a PD parameter can be derived. |

---
<sub>Generated by `docs.py` (scholarv2)</sub>
